Managers
DuPage Medical Group has closed the formation of a strategic partnership with funds managed by the private equity group Ares Management.
The investment by Ares will enable continued support for growth initiatives across the entire organisation, including DMG’s practice management company, DMG Practice Management Solutions, and DMG’s subsidiary, Boncura Health Solutions. The USD1.45 billion transaction closed on 15 August, 2017.
Under the terms of the transaction, DMG’s physician group, DuPage Medical Group Ltd, will remain 100 per cent physician-owned-and-directed, and DMG physicians will retain a significant ownership stake in the practice management company. As part of its investment, Ares
Deutsche Asset Management (Deutsche AM) has provided a EUR45 million mezzanine facility to Ares Management on two designer outlet centres located in the French cities of Troyes and Roubaix.
Andrea Vanni, Head of European Real Estate Debt Investments for Deutsche AM, says: “We are excited to be a part of the financing structure and to have supported Ares on such quality assets.”
NorthEdge Capital has invested in Bridge Farm Nurseries (Bridge Farm), a producer of ornamental plants, flowers and herbs in the UK, backing a management buyout from its family shareholders. It is the first deal for the firm’s recently opened Midlands office.
Founded in 1988 and headquartered in Spalding in Lincolnshire, Bridge Farm works with major UK supermarkets under the brand name Neame Lea, the 2017 UK Grower of the Year, where outdoor plants, flowers and herbs are of increasing importance as a category. Bridge Farm’s core supermarket customer base, which includes Tesco and Aldi, is growing faster than the overall
Round13 Capital, a Toronto-based venture capital firm led by Lavalife co-founder Bruce Croxon and seasoned technology investor John Eckert, has closed a CAD95 million fund to invest in growth stage Canadian companies.
Round13 has made three investments since the fund closed, primarily in early-stage B2B software companies including Statflo, Hubdoc, and TouchBistro. The team’s investments will be looking to fill the gap for startups in Canada needing up to CAD5 million in capital to drive sales and marketing.
“We launched Round13 because there aren’t enough venture firms led by seasoned entrepreneurs who have been in the trenches and successfully
Options, a provider of cloud-enabled managed services to the global capital markets, has secured a significant investment from Bregal Sagemount, a New York-based private equity firm focused on growth-oriented investments.
The transaction, which sees Bregal Sagemount invest nearly USD100 million in Options, will enable the firm’s executive team to pursue strategic growth initiatives, invest further in platform innovations, and expand Options’ reach in key financial centres globally.
Options, founded in 1993 as a hedge fund technology services provider, has enjoyed a period of rapid growth in recent years and now finds itself as an established market leader in outsourced
Private equity deal volumes and valuations are beginning to diverge with the pace of PE investment activity slowing year over year while valuations have climbed to a 10-year high, according to Murray Devine’s inaugural H1 Private Equity Valuations Report.
The report, which analyses data provide by PitchBook to examine trends in PE deal volume and valuation multiples for the first six months of 2017, reveals that this is a tendency more common near the end of a market cycle when sponsors typically target high-quality asset with defensible market positions and lower-quality businesses may fail to trade hands due to mismatched
Preqin’s most recent survey finds that institutional investors view mezzanine funds as one of the most promising areas of the private debt market, leading to increased fundraising for the fund type in recent quarters.
Almost half see mezzanine funds as offering the best risk/return profile, and four out of ten think they offer the best opportunities at present. As a result, investors are seeking out mezzanine investments: the greatest proportion of active investor mandates tracked by Preqin are for mezzanine vehicles. Increased investor interest may partly explain strong fundraising in recent years – 2016 was a record year for mezzanine
Private equity firm Calculus Capital, a leading EIS and VCT investor, has completed its third deal in two weeks, investing GBP2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells.
Axol supplies high quality human cells – especially live human neurons – created by stem cell technology, to many of the world’s biggest and best-known pharma companies and research institutions. These cells are used for medical research, disease modelling and drug development. Axol’s impressive client list includes top global pharmaceutical and biotech companies as well as leading academic institutes, such as
An affiliate of HIG Capital (HIG), a global private equity investment firm with USD22 billion of equity capital under management, has acquired NCI, a diversified IT and professional services company that provides software development, information assurance, IT system engineering and modernisation and other enterprise IT solutions primarily to the US Department of Defence, Intelligence Community, and federal health and civilian agencies.
Paul Dillahay, CEO of NCI, says: “We are excited about our partnership with HIG and what it means for our customers and employees. This partnership with HIG Capital will offer NCI an opportunity to accelerate our growth strategy; enhance
NGX Bio has closed a USD3 million funding round led by 180 Degree Capital Corp with participation from Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors.
NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally. Demand for sequencing services is growing exponentially. NGX Bio’s platform matches the sequencing needs of customers with providers who have available sequencing capacity. Customers are able to purchase a wide range of
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
